ResearcherLeiden University Medical CenterNo recent work listed

Sumit Kumar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0102-0567; OpenAlex author ID A5067000651. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical mode… Co-author DOI 10.1136/gutjnl-2021-324834 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mark J.A. Schoonderwoerd · 1 shared paper, 2022 · strength 0.13
- Paper Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell… DOI 10.1136/gutjnl-2021-324834 ↗
Noel F.C.C. de Miranda · 1 shared paper, 2022 · strength 0.13
- Paper Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell… DOI 10.1136/gutjnl-2021-324834 ↗
Lukas J.A.C. Hawinkels · 1 shared paper, 2022 · strength 0.13
- Paper Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell… DOI 10.1136/gutjnl-2021-324834 ↗
Alfred C.O. Vertegaal · 1 shared paper, 2022 · strength 0.13
- Paper Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell… DOI 10.1136/gutjnl-2021-324834 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.